Cargando…

Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy

An assessment of the risk of Graves’ orbitopathy (GO) is an important challenge in Graves’ disease (GD) management. The purpose of this study was to compare non-genetic parameters in GD patients with and without GO in order to find novel risk factors and to verify the factors already reported. A tot...

Descripción completa

Detalles Bibliográficos
Autores principales: Zawadzka-Starczewska, Katarzyna, Stasiak, Bartłomiej, Wojciechowska-Durczyńska, Katarzyna, Lewiński, Andrzej, Stasiak, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779411/
https://www.ncbi.nlm.nih.gov/pubmed/36554821
http://dx.doi.org/10.3390/ijerph192416941
_version_ 1784856603099398144
author Zawadzka-Starczewska, Katarzyna
Stasiak, Bartłomiej
Wojciechowska-Durczyńska, Katarzyna
Lewiński, Andrzej
Stasiak, Magdalena
author_facet Zawadzka-Starczewska, Katarzyna
Stasiak, Bartłomiej
Wojciechowska-Durczyńska, Katarzyna
Lewiński, Andrzej
Stasiak, Magdalena
author_sort Zawadzka-Starczewska, Katarzyna
collection PubMed
description An assessment of the risk of Graves’ orbitopathy (GO) is an important challenge in Graves’ disease (GD) management. The purpose of this study was to compare non-genetic parameters in GD patients with and without GO in order to find novel risk factors and to verify the factors already reported. A total number of 161 people, 70 with GO and 91 non-GO patients were included in this study. GO was confirmed to be associated with smoking, older age, higher TSH receptor antibodies (TRAb) and lower thyroglobulin antibody (TgAb) levels and hypercholesterolemia. We demonstrated the latter correlation even for only a mild increase in LDL cholesterol. Importantly, our study provides novel potential GO risk factors, including higher serum creatinine levels, higher MCV and lower PLT. If further confirmed, these new, simple and easily accessible potential GO markers may constitute valuable auxiliary markers in GO risk assessments. We additionally proved that in moderate to severe GO, gender-related differences attenuate. No impact of vitamin D deficiency in GO development in patients with 25-hydroxyvitamin D [25(OH)D] > 20 ng/mL was found. The present report provides a set of GO risk factors, which can be used as a precise tool for an individual GO risk assessment.
format Online
Article
Text
id pubmed-9779411
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97794112022-12-23 Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy Zawadzka-Starczewska, Katarzyna Stasiak, Bartłomiej Wojciechowska-Durczyńska, Katarzyna Lewiński, Andrzej Stasiak, Magdalena Int J Environ Res Public Health Article An assessment of the risk of Graves’ orbitopathy (GO) is an important challenge in Graves’ disease (GD) management. The purpose of this study was to compare non-genetic parameters in GD patients with and without GO in order to find novel risk factors and to verify the factors already reported. A total number of 161 people, 70 with GO and 91 non-GO patients were included in this study. GO was confirmed to be associated with smoking, older age, higher TSH receptor antibodies (TRAb) and lower thyroglobulin antibody (TgAb) levels and hypercholesterolemia. We demonstrated the latter correlation even for only a mild increase in LDL cholesterol. Importantly, our study provides novel potential GO risk factors, including higher serum creatinine levels, higher MCV and lower PLT. If further confirmed, these new, simple and easily accessible potential GO markers may constitute valuable auxiliary markers in GO risk assessments. We additionally proved that in moderate to severe GO, gender-related differences attenuate. No impact of vitamin D deficiency in GO development in patients with 25-hydroxyvitamin D [25(OH)D] > 20 ng/mL was found. The present report provides a set of GO risk factors, which can be used as a precise tool for an individual GO risk assessment. MDPI 2022-12-16 /pmc/articles/PMC9779411/ /pubmed/36554821 http://dx.doi.org/10.3390/ijerph192416941 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zawadzka-Starczewska, Katarzyna
Stasiak, Bartłomiej
Wojciechowska-Durczyńska, Katarzyna
Lewiński, Andrzej
Stasiak, Magdalena
Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy
title Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy
title_full Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy
title_fullStr Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy
title_full_unstemmed Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy
title_short Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy
title_sort novel insight into non-genetic risk factors of graves’ orbitopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779411/
https://www.ncbi.nlm.nih.gov/pubmed/36554821
http://dx.doi.org/10.3390/ijerph192416941
work_keys_str_mv AT zawadzkastarczewskakatarzyna novelinsightintonongeneticriskfactorsofgravesorbitopathy
AT stasiakbartłomiej novelinsightintonongeneticriskfactorsofgravesorbitopathy
AT wojciechowskadurczynskakatarzyna novelinsightintonongeneticriskfactorsofgravesorbitopathy
AT lewinskiandrzej novelinsightintonongeneticriskfactorsofgravesorbitopathy
AT stasiakmagdalena novelinsightintonongeneticriskfactorsofgravesorbitopathy